LOXL1‑AS1 promotes thymoma and thymic carcinoma progression by regulating miR‑525‑5p‑<em>HSPA9</em>

Wang,Jin; Huang,Haihua; Zhang,Xiaomiao; Ma,Haitao

doi:10.3892/or.2021.8068

LOXL1‑AS1 promotes thymoma and thymic carcinoma progression by regulating miR‑525‑5p‑HSPA9

Authors:
- Jin Wang
- Haihua Huang
- Xiaomiao Zhang
- Haitao Ma
View Affiliations

Affiliations: Department of Cardiothoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China, Department of Thoracic Surgery, Shanghai General Hospital, Shanghai 200080, P.R. China
Published online on: April 27, 2021 https://doi.org/10.3892/or.2021.8068
Article Number: 117
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Due to the lack of specific symptoms in early thymic epithelial tumours (TETs), patients are mostly in the advanced stage at the time of presentation. The aim of the present study was to explore the mechanism by which the long noncoding RNA (lncRNA) LOXL1‑AS1 affects thymoma and thymic carcinoma progression by targeting the miR‑525‑5p‑HSPA9 axis. Bioinformatics was used to analyse the process of LOXL1‑AS1 targeting miR‑525‑5p‑HSPA9 and its expression characteristics in TET. The relationships between LOXL1‑AS1, miR‑525‑5p, HSPA9 and prognosis were analysed. The dual luciferase reporter assay was applied to verify targeting. The gene was knocked down or overexpressed by plasmid transfection. Cell counting kit 8 (CCK‑8) assay, flow cytometry and Transwell assay were used to detect cell viability, apoptosis and invasion ability, respectively. Proteins and RNAs were examined by western blot analysis and qPCR, respectively. A tumour‑burdened assay was used to perform in vivo verification. LOXL1‑AS1 and HSPA9 were overexpressed in thymoma and thymic carcinoma; high levels of LOXL1‑AS1 and HSPA9 were associated with poor prognosis, and there was a significant positive correlation between their levels. Downregulation of miR‑525‑5p expression was also associated with poor prognosis of patients. Clinical trials also demonstrated the same trends. miR‑525‑5p inhibited the expression of HSPA9 protein by targeting the 3'‑untranslated region (UTR) of HSPA9 mRNA. LOXL1‑AS1 promoted the expression of HSPA9 as a sponge targeting miR‑525‑5p. Animal experiment results also showed that knockdown of miR‑525‑5p promoted cancer by promoting the expression of HSPA9. In conclusion, LOXL1‑AS1 and HSPA9 are highly expressed in thymoma and thymic carcinoma; miR‑525‑5p is expressed at low levels in thymoma and thymic carcinoma; and downregulation of miR‑525‑5p is associated with poor prognosis. In summary, this study demonstrates that LOXL1‑AS1 acts as a sponge that targets miR‑525‑5p to promote HSPA9 expression, thereby promoting the growth and invasion and inhibiting apoptosis of thymoma and thymic carcinoma cells.

View Figures

View References

1	Roden AC: Evolution of classification of thymic epithelial tumors in the Era of Dr Thomas V. Colby. Arch Pathol Lab Med. 141:232–246. 2017. View Article : Google Scholar : PubMed/NCBI
2	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
3	Travis WD, Brambilla E, Burke AP, Marx A and Nicholson AG: Introduction to The 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart. J Thorac Oncol. 10:1240–1242. 2015. View Article : Google Scholar : PubMed/NCBI
4	Du J and Zhou XJ: Precise diagnosis and treatment of thymic epithelial tumors based on molecular biomarkers. Crit Rev Oncog. 22:507–514. 2017. View Article : Google Scholar : PubMed/NCBI
5	Hamanaka K, Koyama T, Matsuoka S, Takeda T, Miura K, Yamada K, Hyogotani A, Seto T, Okada K and Ito KI: Analysis of surgical treatment of Masaoka stage III–IV thymic epithelial tumors. Gen Thorac Cardiovasc Surg. 66:731–735. 2018. View Article : Google Scholar : PubMed/NCBI
6	Shapiro M and Korst RJ: Surgical approaches for Stage IVA thymic epithelial tumors. Front Oncol. 3:3322014. View Article : Google Scholar : PubMed/NCBI
7	Du Y and Wang Y, Tang J, Ge J, Qin Q, Jiang LI, Liu X, Zhu X and Wang Y: Pancreatic metastasis resulting from thymic neuroendocrine carcinoma: A case report. Oncol Lett. 11:1907–1910. 2016. View Article : Google Scholar : PubMed/NCBI
8	Khandelwal A, Sholl LM, Araki T, Ramaiya NH, Hatabu H and Nishino M: Patterns of metastasis and recurrence in thymic epithelial tumours: Longitudinal imaging review in correlation with histological subtypes. Clin Radiol. 71:1010–1017. 2016. View Article : Google Scholar : PubMed/NCBI
9	Lu TX and Rothenberg ME: MicroRNA. J Allergy Clin Immunol. 141:1202–1207. 2018. View Article : Google Scholar : PubMed/NCBI
10	Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP and Burge CB: Prediction of mammalian microRNA targets. Cell. 115:787–798. 2003. View Article : Google Scholar : PubMed/NCBI
11	Fischer SEJ: RNA interference and microRNA-mediated silencing. Curr Protoc Mol Biol. 112:26 1.1–26. 1 5. 2015. View Article : Google Scholar : PubMed/NCBI
12	Mercer TR, Dinger ME and Mattick JS: Long non-coding RNAs: Insights into functions. Nat Rev Genet. 10:155–159. 2009. View Article : Google Scholar : PubMed/NCBI
13	Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, Chinappi M, Tramontano A and Bozzoni I: A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell. 147:358–369. 2011. View Article : Google Scholar : PubMed/NCBI
14	Liu XH, Sun M, Nie FQ, Ge YB, Zhang EB, Yin DD, Kong R, Xia R, Lu KH, Li JH, et al: Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer. Mol Cancer. 13:922014. View Article : Google Scholar : PubMed/NCBI
15	Ye S, Yang L, Zhao X, Song W, Wang W and Zheng S: Bioinformatics method to predict two regulation mechanism: TF-miRNA-mRNA and lncRNA-miRNA-mRNA in pancreatic cancer. Cell Biochem Biophys. 70:1849–1858. 2014. View Article : Google Scholar : PubMed/NCBI
16	Berrondo C, Flax J, Kucherov V, Siebert A, Osinski T, Rosenberg A, Fucile C, Richheimer S and Beckham CJ: Expression of the long non-coding RNA HOTAIR correlates with disease progression in bladder cancer and is contained in bladder cancer patient urinary exosomes. PLoS One. 11:e01472362016. View Article : Google Scholar : PubMed/NCBI
17	Xiao B, Zhang W, Chen L, Hang J, Wang L, Zhang R, Liao Y, Chen J, Ma Q, Sun Z and Li L: Analysis of the miRNA-mRNA-lncRNA network in human estrogen receptor-positive and estrogen receptor-negative breast cancer based on TCGA data. Gene. 658:28–35. 2018. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Giaccone G, Kim C, Thompson J, McGuire C, Kallakury B, Chahine JJ, Manning M, Mogg R, Blumenschein WM, Tan MT, et al: Pembrolizumab in patients with thymic carcinoma: A single-arm, single-centre, phase 2 study. Lancet Oncol. 19:347–355. 2018. View Article : Google Scholar : PubMed/NCBI
20	Wang Y, Xu L, Du T, Gao Y, Wu Z and Luo D: A nomogram predicting recurrence and guiding adjuvant radiation for thymic carcinoma after resection. Ann Thorac Surg. 106:257–263. 2018. View Article : Google Scholar : PubMed/NCBI
21	Lu Z and Li Y, Takwi A, Li B, Zhang J, Conklin DJ, Young KH, Martin R and Li Y: miR-301a as an NF-kappaB activator in pancreatic cancer cells. EMBO J. 30:57–67. 2011. View Article : Google Scholar : PubMed/NCBI
22	Nishikawa R, Goto Y, Sakamoto S, Chiyomaru T, Enokida H, Kojima S, Kinoshita T, Yamamoto N, Nakagawa M, Naya Y, et al: Tumor-suppressive microRNA-218 inhibits cancer cell migration and invasion via targeting of LASP1 in prostate cancer. Cancer Sci. 105:802–811. 2014. View Article : Google Scholar : PubMed/NCBI
23	Peng Y, Zhang X, Ma Q, Yan R, Qin Y, Zhao Y, Cheng Y, Yang M, Wang Q, Feng X, et al: MiRNA-194 activates the Wnt/β-catenin signaling pathway in gastric cancer by targeting the negative Wnt regulator, SUFU. Cancer Lett. 385:117–127. 2017. View Article : Google Scholar : PubMed/NCBI
24	Bellissimo T, Ganci F, Gallo E, Sacconi A, Tito C, De Angelis L, Pulito C, Masciarelli S, Diso D, Anile M, et al: Thymic epithelial tumors phenotype relies on miR-145-5p epigenetic regulation. Mol Cancer. 16:882017. View Article : Google Scholar : PubMed/NCBI
25	Bellissimo T, Russo E, Ganci F, Vico C, Sacconi A, Longo F, Vitolo D, Anile M, Disio D, Marino M, et al: Circulating miR-21-5p and miR-148a-3p as emerging non-invasive biomarkers in thymic epithelial tumors. Cancer Biol Ther. 17:79–82. 2016. View Article : Google Scholar : PubMed/NCBI
26	Guo D, Ye Y, Qi J, Xu L, Zhang L, Tan X, Tan Z, Yu X, Zhang Y, Ma Y and Li Y: MicroRNA-195a-5p inhibits mouse medullary thymic epithelial cells proliferation by directly targeting Smad7. Acta Biochim Biophys Sin (Shanghai). 48:290–297. 2016. View Article : Google Scholar : PubMed/NCBI
27	Enkner F, Pichlhofer B, Zaharie AT, Krunic M, Holper TM, Janik S, Moser B, Schlangen K, Neudert B, Walter K, et al: Molecular profiling of thymoma and thymic carcinoma: Genetic differences and potential novel therapeutic targets. Pathol Oncol Res. 23:551–564. 2017. View Article : Google Scholar : PubMed/NCBI
28	Chen M and Liu LX: miR-525-5p repressed metastasis and anoikis resistance in cervical cancer via Blocking UBE2C/ZEB1/2 Signal Axis. Dig Dis Sci. 65:2442–2451. 2020. View Article : Google Scholar : PubMed/NCBI
29	Qi L, Gao C, Feng F, Zhang T, Yao Y, Wang X, Liu C, Li J, Li J and Sun C: MicroRNAs associated with lung squamous cell carcinoma: New prognostic biomarkers and therapeutic targets. J Cell Biochem. 120:18956–18966. 2019. View Article : Google Scholar : PubMed/NCBI
30	Jiang HY and Wang ZJ: ADPGK-AS1 promotes the progression of colorectal cancer via sponging miR-525 to upregulate FUT1. Eur Rev Med Pharmacol Sci. 24:2380–2386. 2020.PubMed/NCBI
31	Chang H, Zhang X, Li B and Meng X: MAGI2-AS3 suppresses MYC signaling to inhibit cell proliferation and migration in ovarian cancer through targeting miR-525-5p/MXD1 axis. Cancer Med. 9:6377–6386. 2020. View Article : Google Scholar : PubMed/NCBI
32	Cybula M, Wieteska L, Jozefowicz-Korczynska M, Karbownik MS, Grzelczyk WL and Szemraj J: New miRNA expression abnormalities in laryngeal squamous cell carcinoma. Cancer Biomark. 16:559–568. 2016. View Article : Google Scholar : PubMed/NCBI
33	Starenki D, Sosonkina N, Hong SK, Lloyd RV and Park JI: Mortalin (GRP75/HSPA9) promotes survival and proliferation of thyroid carcinoma cells. Int J Mol Sci. 20:20692019. View Article : Google Scholar : PubMed/NCBI
34	Peng C, Yang P, Cui Y, He M, Liang L and Di Y: HSPA9 overexpression inhibits apoptin-induced apoptosis in the HepG2 cell line. Oncol Rep. 29:2431–2437. 2013. View Article : Google Scholar : PubMed/NCBI
35	Hou S, Shan M, Gao C, Feng X, Yang Y, Zhang R, He Y, Zhang G and Zhang L: PCDHGB7 increases chemosensitivity to carboplatin by inhibiting HSPA9 via inducing apoptosis in breast cancer. Dis Markers. 2019:61315482019. View Article : Google Scholar : PubMed/NCBI
36	Xia T, Liao Q, Jiang X, Shao Y, Xiao B, Xi Y and Guo J: Long noncoding RNA associated-competing endogenous RNAs in gastric cancer. Sci Rep. 4:60882014. View Article : Google Scholar : PubMed/NCBI
37	Xu J, Li Y, Lu J, Pan T, Ding N, Wang Z, Shao T, Zhang J, Wang L and Li X: The mRNA related ceRNA-ceRNA landscape and significance across 20 major cancer types. Nucleic Acids Res. 43:8169–8182. 2015. View Article : Google Scholar : PubMed/NCBI
38	Luo Z, Li Y, Liu X, Luo M, Xu L, Luo Y, Xiao B and Yang H: Systems biology of myasthenia gravis, integration of aberrant lncRNA and mRNA expression changes. BMC Med Genomics. 8:132015. View Article : Google Scholar : PubMed/NCBI
39	Kong X, Wang J, Cao Y, Zhang H, Lu X, Wang Y, Bo C, Wang T, Li S, Tian K, et al: The long noncoding RNA MALAT-1 functions as a competing endogenous RNA to regulate MSL2 expression by sponging miR-338-3p in myasthenia gravis. J Cell Biochem. 120:5542–5550. 2019. View Article : Google Scholar : PubMed/NCBI
40	Wang H, Li L and Yin L: Silencing LncRNA LOXL1-AS1 attenuates mesenchymal characteristics of glioblastoma via NF-ĸB pathway. Biochem Biophys Res Commun. 500:518–524. 2018. View Article : Google Scholar : PubMed/NCBI
41	Gao R, Zhang R, Zhang C, Liang Y and Tang W: LncRNA LOXL1-AS1 promotes the proliferation and metastasis of medulloblastoma by activating the PI3K/AKT pathway. Anal Cell Pathol (Amst). 2018:92756852018.PubMed/NCBI
42	Chen S, Li W and Guo A: LOXL1-AS1 predicts poor prognosis and promotes cell proliferation, migration, and invasion in osteosarcoma. Biosci Rep. 39:BSR201904472019. View Article : Google Scholar : PubMed/NCBI
43	Sun Q, Li J, Li F, Li H, Bei S, Zhang X and Feng L: LncRNA LOXL1-AS1 facilitates the tumorigenesis and stemness of gastric carcinoma via regulation of miR-708-5p/USF1 pathway. Cell Prolif. 52:e126872019. View Article : Google Scholar : PubMed/NCBI
44	Bai T, Liu Y and Li B: LncRNA LOXL1-AS1/miR-let-7a-5p/EGFR-related pathway regulates the doxorubicin resistance of prostate cancer DU-145 cells. IUBMB life. 71:1537–1551. 2019. View Article : Google Scholar : PubMed/NCBI
45	Zhang B, Zhou M, Zou L, Miao J, Wang Y, Li Y, Lu S and Yu J: Long non-coding RNA LOXL1-AS1 acts as a ceRNA for miR-324-3p to contribute to cholangiocarcinoma progression via modulation of ATP-binding cassette transporter A1. Biochem Biophys Res Commun. 513:827–833. 2019. View Article : Google Scholar : PubMed/NCBI
46	Long B, Li N, Xu XX, Li XX, Xu XJ, Liu JY and Wu ZH: Long noncoding RNA LOXL1-AS1 regulates prostate cancer cell proliferation and cell cycle progression through miR-541-3p and CCND1. Biochem Biophys Res Commun. 505:561–568. 2018. View Article : Google Scholar : PubMed/NCBI